29Z6 has a novel HER3-dependent mechanism of action. It demonstrated strong in vitro and in vivo activity and effective against many common cancers with HER3 overexpression such as pancreatic cancer, lung cancer, head and neck cancer, and breast cancer. The drug showed no toxicity in preclinical development. 29Z6 has strong Intellectual IP protection in place. The International Patent Office has granted all of the 29Z6 claims. The antibody has first-and best-in-class potential with opportunity for single-agent and combination therapy.FUTURE OF 29Z6
29Z6 preclinical evaluations, including in vitro and in vivo pharmacology (including initial evidence of efficacy in an appropriate animal model of the disease) has been completed successfully. The next steps are optimizing the manufacturing process, and scaling up production to support clinical evaluations (i.e., chemistry, manufacturing, and controls; CMC).